Table of Content

1. PREFACE
1.1. Plasma Fractionation Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Blood Plasma
3.2.1. Plasma Collection
3.2.2. Plasma Screening
3.2.3. Plasma Fractionation
3.3. Applications of Plasma Fractionation
3.4. Challenges Associated with Plasma Fractionation
3.5. Need for Third-party Service Providers
3.5.1. Overview of Third-party Service Providers
3.6. Future Perspectives

4. PLASMA FRACTIONATION: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Plasma Fractionation: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region)
4.2.4. Analysis by Location of Headquarters (Country)
4.2.5. Analysis by Year of Establishment and Location of Headquarters (Region)
4.2.6. Analysis by Company Size and Location of Headquarters (Region)
4.2.7. Analysis by Type of Company
4.2.8. Analysis by Location of Plasma Fractionation Facilities (Region)
4.2.9. Analysis by Location of Plasma Collection Facility
4.2.10. Analysis by Availability of Patented / Proprietary Technology
4.2.11. Analysis by Additional Fractionation Capabilities
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
4.2.14. Analysis by Therapeutic Areas of Plasma-derived Products
4.2.15. Analysis by End Users
4.2.16. Information on Plasma Fractionation Capacity and Accreditation / Certification
4.2.17. Information on Upcoming Plasma Fractionation Facilities
4.2.18. Information on Companies Previously Involved in Plasma Fractionation

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: In-house Manufacturers
5.4.1. Players based in North America and Europe
5.4.2. Players based in Asia-Pacific and Rest of the World
5.5. Company Competitiveness Analysis: In-house Manufacturers and Contract Service Providers
5.5.1. Players based in North America and Europe
5.5.2. Players based in Asia-Pacific and Rest of the World

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Baxter
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Plasma Fractionation Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.3. Companies Headquartered in Europe
6.3.1. Grifols
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Plasma Fractionation Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Kedrion
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Plasma Fractionation Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Octapharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Plasma Fractionation Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.4. Companies Headquartered in Asia-Pacific
6.4.1. CSL
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Plasma Fractionation Portfolio
6.4.1.5. Recent Developments and Future Outlook
6.4.2. Takeda Pharmaceutical
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Plasma Fractionation Portfolio
6.4.2.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Plasma Fractionation: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Purpose of Agreement
7.3.5. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
7.3.6. Analysis by Type of Partner
7.3.7. Analysis by Year of Partnership and Type of Partner
7.3.8. Analysis by Type of Partnership and Type of Partner
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.4. Analysis by Geography
7.4.1. Local and International Agreements
7.4.2. Intracontinental and Intercontinental Agreements

8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Expansion Models
8.3. Plasma Fractionation: Recent Expansions
8.3.1. Analysis by Year of Expansion
8.3.2. Analysis by Type of Expansion
8.3.3. Analysis by Year and Type of Expansion
8.3.4. Analysis by Type of Facility
8.3.5. Analysis by Location of Expanded Facility
8.3.6. Analysis by Year and Location of Expanded Facility
8.3.7. Analysis by Plasma-derived Therapeutic Products Manufactured
8.3.8. Most Active Players: Analysis by Number of Expansions

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.2.1. Annual Plasma Fractionation Capacity
9.2.1.1. Analysis by Company Size
9.2.1.2. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
9.2.1.3. Analysis by Scale of Operation
9.2.2. Analysis by Location of Plasma Fractionation Facility
9.2.3 .Analysis by Location of Headquarters
9.3. Concluding Remarks

10. MARKET SIZING AND OPPURTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035
10.3.1. Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035
10.3.1.1. Plasma Fractionation Market for In-house Manufacturers, 2023-2035
10.3.1.2. Plasma Fractionation Market for Contract Service Providers, 2023-2035
10.3.2. Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035
10.3.2.1. Plasma Fractionation Market for Preclinical, 2023-2035
10.3.2.2. Plasma Fractionation Market for Clinical, 2023-2035
10.3.2.3. Plasma Fractionation Market for Commercial, 2023-2035
10.3.3. Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035
10.3.3.1. Plasma Fractionation Market for Albumins, 2023-2035
10.3.3.2. Plasma Fractionation Market for Coagulation Factors, 2023-2035
10.3.3.3. Plasma Fractionation Market for Immunoglobulins, 2023-2035
10.3.3.4. Plasma Fractionation Market for Protease Inhibitors, 2023-2035
10.3.3.5. Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035
10.3.4. Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035
10.3.4.1. Plasma Fractionation Market for Hematological Disorders, 2023-2035
10.3.4.2. Plasma Fractionation Market for Hepatic Disorders, 2023-2035
10.3.4.3. Plasma Fractionation Market for Immunological Disorders, 2023-2035
10.3.4.4. Plasma Fractionation Market for Neurological Disorders, 2023-2035
10.3.4.5. Plasma Fractionation Market for Other Disorders, 2023-2035
10.3.5. Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035
10.3.5.1. Plasma Fractionation Market in North America, 2023-2035
10.3.5.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.5.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.5.4. Plasma Fractionation Market in Rest of the World, 2023-2035
10.3.6. Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035
10.3.6.1. Plasma Fractionation Market in North America, 2023-2035
10.3.6.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.6.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.6.4. Plasma Fractionation Market in Rest of the World, 2023-2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS